ocular disorder
Johnson & Johnson's X-Linked Retinitis Pigmentosa Gene Therapy Fails Phase III Trial
Although the trial didn't show statistically significant improvements in functional vision, J&J said the data were "directionally supportive."
On the heels of its acquisition by Ocuphire Pharma, Opus is planning next steps for its Leber congenital amaurosis type 5 gene therapy.
The biotech firm closed an oversubscribed Series C funding round, proceeds from which it will use to advance ATSN-201 and its preclinical pipeline.
AI models trained on optical coherence tomography scans to detect eye diseases are showing promise in diagnosing heart disease, stroke, and dementia.
ICER Finds Nanoscope Retinal Gene Therapy Cost Effective in $67,400 to $101,300 Price Range
Nanoscope Therapeutics has said it plans to seek regulatory approval for its advanced retinitis pigmentosa gene therapy MCO-010 early this year.